Abstract: Dental desensitizing solutions and methods of using the solutions are disclosed. The solution may include an active ingredient, the active ingredient, when applied to a tooth, being configured to react with calcium in the tooth to produce a plurality of acid-resistant crystals that at least partially occlude dentinal tubules in the tooth. The solution may include a solubility enhancer, the solubility enhancer increasing the solubility of the active ingredient in the solution. The active ingredient may be oxalic acid, potassium salt dihydrate and the solubility enhancer may be sodium hydroxide, however, other active ingredients and solubility enhancers are disclosed. The solution may be applied to the tooth dentin and/or cementum to reduce hypersensitivity or pain from certain stimuli. The solution may increase the solubility of the active ingredient by at least 1.0 g/L at a given temperature. The solution may include at least 0.3 g/L of the solubility enhancer.

Abstract: Peptides that bind with high affinity to oral cavity surfaces, such as tooth enamel, have been discovered. The peptides exhibit antibacterial and mineralizing abilities, and are useful in many aspects of oral care. A preferred peptide includes the amino acid sequence AKRHHGYKRKFH-SpSp. The peptides can be included in oral care compositions such as toothpastes and mouthwashes. The oral care compositions can be used in methods to treat or prevent diseases or conditions induced by acidophilic oral bacteria. Exemplary methods include reducing or preventing tooth decay or demineralization, biofilm or dental plaque formation, and/or bacterial adhesion to a tooth surface; and promoting mineralization of teeth surfaces.

Abstract: The invention relates to a method of cultivating soybean exposed to at least one fungal disease comprising a step of applying to said cultivated soybean an effective treatment with at least one organo-chemical fungicide in combination with at least two applications of a phytosterol composition comprising at least one phytosterol and at least one sucrose fatty acid ester to increase the yield of said cultivated soybean and/or to reduce the effects of said at least one fungal disease in comparison to soybeans under similar conditions treated only with the organo-chemical fungicide treatment.

Abstract: A two phase system for administering a dose of an active to an animal having a liquid aqueous phase and a liquid oil phase, wherein the liquid oil phase has a dosage of at least one active, at least one oil and at least one surfactant, and the liquid oil phase has a density less than about 1.0 g/mL. The system is administered in an individual drinking container, such as a water bucket or water dish. The surfactant is non-water soluble and has an HLB of less than about 6.0. The oil phase adheres to tongue and mouth tissue of the pet or livestock that consumes it from the water bucket or water dish.

Abstract: Described herein are oral care compositions comprising vitamin D, or a derivative thereof; an alkanoic acid of formula R—COOH or an alkali metal salt thereof, wherein R is a C1 to C13 hydrocarbyl group; and an orally acceptable carrier. Methods of making and using same are also described.

Abstract: A cosmetic kit is disclosed having a container and a shaving cap. The container comprises interior chamber containing a solidified gel of a micellar solution and a dispensing opening that exposes an outer surface of the solidified gel. The exposed surface of the solidified gel to a surface, like skin, and can be cleaned with the shaving cap, which removes at least a portion of the exposed surface of the solidified gel. The shaving cap comprises a planer surface and one or more openings or slits through the planar surface having shaving edges that shave the exposed surface of the solidified gel when applied against the exposed surface, for example, by rotating the shaving cap relative to the container with sufficient force to overcome shearing resistance of the solidified gel. The cosmetic kit is particularly useful for hygienically cleansing the skin.

Abstract: A staurosporine-emamectin benzoate suspending agent and a preparation method and application thereof. The suspending agent contains staurosporine and emamectin benzoate. Among them, the mass ratio of staurosporine to emamectin benzoate is 1-9:9-1. The suspending agent in the present invention can be prepared by adding an appropriate amount of wetting agent, dispersing agent, wetting & dispersing agent, thickener, stabilizer, antifreeze, pH adjuster and defoaming agent into staurosporine and emamectin benzoate. The preparation is highly efficient, low-toxic and pollution-free. After being sprayed, it is distributed on the surface of crops as fine particles, which is more conducive to the direct control of pests, can reduce the dosage of emamectin benzoate, enhance the effect of pest control, and effectively delay the resistance.

Abstract: An object of the present invention is to provide a lipid particle that can be produced without using a PEG-modified lipid, or that exhibits higher drug effects, safety, or stability than those of a lipid particle produced using a PEG-modified lipid; or that has immunokinetics different from those of a lipid particle produced using a PEG-modified lipid. A lipid particle comprising an ionized lipid, a phospholipid, and a sterol as lipid components of the lipid particle, and a modified polysaccharide containing a hydrophobic group.

Abstract: The present invention provides new dental care products comprising self-assembling peptides that are capable of undergoing self-assembly at a certain pH that are useful in dental care, in particular, useful for reducing or preventing demineralisation of teeth of a subject, in particular, for reducing or preventing further demineralisation of teeth of a subject. The dental care products comprises self-assembling peptides, in particular, comprise self-assembling peptides comprising the sequence of SEQ ID NO: 21, that are capable of undergoing self-assembly at a pH below 7.5, wherein the self-assembling peptides are essentially present in the dental care product in assembled form, and a pharmaceutically acceptable basis. The dental care product is an essentially solid product selected from the group consisting of chewing gum, soft chew, toffee, gelatin gum, chewy candy, chew toy, lozenge. Preferably, it is a chewy product. The dental care product is not abrasive.

Abstract: Provided are fermentation extracts, cosmetic composition, and manufacturing method of fermentation extracts. For this, the present invention discloses a fermentation extract consisting of a glutathione liquid dispersion liposomized using a liquid collagen extract as a solvent and a Lactobacillus fermentation filtrate obtained by stirring and extracting the same at a preset low temperature.

Abstract: The present disclosure provides methods of treating immune evasive cancers using surface functionalized particles alone or in combination with cancer therapeutics.

Abstract: A pharmaceutical composition to be applied to the pulmonary epithelium for the treatment of pulmonary diseases, comprising ibuprofen, arginine, solubilized in a hypertonic alkaline aqueous solution.

Abstract: The present invention relates to the use of sweet steviol glycoside compounds, particularly rebaudioside B, in sweetening compositions. Sweetening compositions comprising selected amounts of rebaudioside B have been shown to possess favorable flavor profiles when compared to other high intensity sweetener compounds and are useful in the preparation of consumables.

Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing an mRNA solution containing low citrate concentration and a lipid solution at an ambient temperature. Thus, the present invention provides an effective, reliable, energy-saving and cost-effective method of encapsulating mRNA into lipid nanoparticles.

Abstract: Described are: a multi-layer oral thin film, comprising at least two layers arranged one on top of the other, which each comprise at least one water-soluble polymer, these at least two layers being connected to one another by at least one sealing, characterised in that the at least one sealing is not provided over the entire surface; a method for producing same; and use thereof as a medicament.

Abstract: A container for use in the treatment and/or prophylaxis of viral infections and/or associated conditions prefilled with a thixotropic gel characterized by a density selected from about 1.02 g/cm3 to about 1.05 g/cm3.

Abstract: Oral care compositions with an anticaries or anticavity effect. Oral care compositions that have one or more hops beta acids, such as from an extract from a species in the Humulus family, and one or more amino acids. Oral care compositions having one or more amino acids and an extract from Humulus lupulus. Methods of use of the disclosed compositions to disrupt biofilm in the oral cavity of a patient in need of treatment.

Abstract: Described are new biodegradable nanoparticle platforms for encapsulation and sustained release of protein therapeutics through a scalable and reproducible method. Specifically nanoparticles comprising a complex comprising a protein, or peptide, and a counter ion polymer are described.

Abstract: The present invention is directed to embodiments of a method for coloring hair using an oxidative hair coloring composition based upon the primary dye compounds MBB, Aminol and optional secondary precursor and coupler compounds PAP, DPE, MAP, AHT and EOAP, a carbonate and/or bicarbonate source, an alkalizer and one or more amino acids. Additional subsidiary precursors and couplers may be included to broaden the color space delivered by the primary dye compounds. The oxidative hair coloring composition is free of resorcinol and C1-C10 alkyl resorcinol. The L*a*b* color space of embodiments of the oxidative hair coloring composition as measured by L*a*b* techniques is about the same as that delivered by the resorcinol based composition.

Abstract: The present disclosure provides a radiotheranostic agent targeting LRRC15 expressed on cells derived from or associated with mesenchymal stem cells. The LRRC15 targeting agent would significantly improve diagnosis and treatment of a broad range of diseases and malignancies. In one embodiment, the LRRC15 targeting agent is a humanized monoclonal antibody (DUNP19) that has high binding affinity to LRRC15 and is internalized by cells expressing LRRC15.